These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Nevada
|
45-2859440
|
|
|
(State or other jurisdiction of incorporation)
|
(I.R.S. Employer Identification No.)
|
|
Large accelerated filer
¨
|
Accelerated filer
¨
|
Non-accelerated filer
¨
|
Smaller reporting company
þ
|
|||
|
(Do not check if a smaller
Reporting company)
|
|
PAGE
|
|||
| PART I - FINANCIAL INFORMATION | |||
|
3
|
|||
|
21
|
|||
|
28
|
|||
|
28
|
|||
| PART II - OTHER INFORMATION | |||
|
29
|
|||
|
29
|
|||
|
29
|
|||
|
30
|
|||
|
30
|
|||
|
30
|
|||
|
30
|
|||
| SIGNATURES | 32 | ||
|
PAGE
|
||
|
4
|
||
|
5
|
||
|
6
|
||
|
7
|
|
March 31,
|
December 31,
|
|||||||
|
2015
|
2014
|
|||||||
|
ASSETS
|
||||||||
|
Current assets
|
||||||||
|
Cash
|
$ | 413,607 | $ | 233,068 | ||||
|
Accounts receivable, less allowance for doubtful accounts of $ 19,061 and $ 4,672 respectively
|
15,946 | 45,070 | ||||||
|
Prepaid expenses and other current assets
|
91,193 | 53,366 | ||||||
|
Total current assets
|
520,746 | 331,504 | ||||||
|
Property and equipment - at cost, less accumulated
depreciation and amortization
|
7,020 | 8,480 | ||||||
|
Investment in associated companies
|
1,128 | 10,750 | ||||||
|
Intangible assets, net
|
885,954 | 1,031,692 | ||||||
|
Total assets
|
$ | 1,414,848 | $ | 1,382,426 | ||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities
|
||||||||
|
Accounts payable
|
$ | 381,744 | $ | 378,023 | ||||
|
Accrued expenses and other current liabilities
|
152,699 | 291,540 | ||||||
|
Current maturities of notes payable
|
105,464 | 118,149 | ||||||
|
Total current liabilities
|
639,907 | 787,712 | ||||||
|
Notes payable, less current maturities
|
82,046 | 91,914 | ||||||
|
Derivative liability - warrants
|
143,663 | 153,154 | ||||||
|
Total liabilities
|
865,616 | 1,032,780 | ||||||
|
Commitments
|
||||||||
|
Stockholders' equity
|
||||||||
|
Preferred stock
|
||||||||
|
Authorized: $0.001 par value, 10,000,000 shares authorized
|
- | - | ||||||
|
Issued and outstanding: nil preferred shares
|
||||||||
|
Common stock
|
||||||||
|
Authorized: $0.001 par value, 290,000,000 shares authorized
|
||||||||
|
Issued and outstanding: 34,689,982 and 33,182,100 respectively
|
34,690 | 33,182 | ||||||
|
Additional paid-in capital
|
6,099,679 | 5,367,771 | ||||||
|
Accumulated other comprehensive loss
|
(282,170 | ) | (178,522 | ) | ||||
|
Accumulated deficit
|
(5,361,733 | ) | (4,794,760 | ) | ||||
|
Total Symbid Corp. stockholders' equity
|
490,466 | 427,671 | ||||||
|
Noncontrolling interests
|
58,766 | (78,025 | ) | |||||
|
Total stockholders' equity
|
549,232 | 349,646 | ||||||
|
Total liabilities and stockholders' equity
|
$ | 1,414,848 | $ | 1,382,426 | ||||
|
Three months ended
|
||||||||
|
March 31,
|
||||||||
|
2015
|
2014
|
|||||||
|
Revenues
|
||||||||
|
Crowd funding
|
$ | 54,394 | $ | 78,055 | ||||
|
Other
|
19,472 | 8,050 | ||||||
|
Total revenues
|
73,866 | 86,105 | ||||||
|
Operating expenses
|
||||||||
|
Selling, general and administrative
|
409,353 | 274,015 | ||||||
|
Professional fees
|
186,670 | 204,713 | ||||||
|
Research and development costs
|
22,242 | 45,975 | ||||||
|
Depreciation and amortization
|
36,938 | 334 | ||||||
|
Total operating expenses
|
655,203 | 525,037 | ||||||
|
Operating loss
|
(581,337 | ) | (438,932 | ) | ||||
|
Other income (expense)
|
||||||||
|
Fair value adjustment derivative liability – warrants
|
(7,274 | ) | 15,264 | |||||
|
Interest expense
|
(2,714 | ) | (5,810 | ) | ||||
|
Government subsidy
|
- | 8,221 | ||||||
|
Gain on sale of investment in Gambitious B.V.
|
11,504 | - | ||||||
|
Other income and expense
|
- | (1,631 | ) | |||||
|
Total other income (expense)
|
1,516 | 16,044 | ||||||
|
Net loss
|
(579,821 | ) | (422,888 | ) | ||||
|
Net loss attributable to noncontrolling interests
|
(12,848 | ) | (11,018 | ) | ||||
|
Net loss attributable to Symbid Corp. stockholders
|
$ | (566,973 | ) | $ | (411,870 | ) | ||
|
Basic and diluted net loss per common stock
|
$ | (0.02 | ) | $ | (0.02 | ) | ||
|
Weighted average number of shares outstanding
|
||||||||
|
Basic and diluted
|
34,079,498 | 26,498,864 | ||||||
|
Share-based compensation expense included in operating expenses:
|
||||||||
|
Selling, general and administrative
|
$ | 120,290 | - | |||||
|
Professional fees
|
44,212 | - | ||||||
|
Research and development costs
|
15,881 | - | ||||||
| $ | 180,383 | - | ||||||
|
Three months ended
|
||||||||
|
March 31,
|
||||||||
|
2015
|
2014
|
|||||||
|
Cash flows from operating activities
|
||||||||
|
Net loss
|
$ | (579,821 | ) | $ | (422,888 | ) | ||
|
Adjustments to reconcile net loss to net cash
|
||||||||
|
used in operating activities
|
||||||||
|
Stock based compensation
|
180,383 | |||||||
|
Depreciation and amortization
|
36,938 | 334 | ||||||
|
Gain on sale of investment in Gambitious
|
(11,504 | ) | ||||||
|
Fair value adjustment derivative liability - warrants
|
7,274 | (15,264 | ) | |||||
|
Deferred government grants
|
- | (8,221 | ) | |||||
|
Provision for doubtful accounts
|
15,485 | 7,007 | ||||||
|
Changes in assets and liabilities
|
||||||||
|
Accounts receivable
|
9,769 | (26,002 | ) | |||||
|
Prepaid expenses and other current assets
|
(45,293 | ) | (6,921 | ) | ||||
|
Accounts payable
|
35,207 | 32,859 | ||||||
|
Accrued expenses and other current liabilities
|
(77,124 | ) | (90,925 | ) | ||||
|
Net cash used in operating activities
|
(428,686 | ) | (530,021 | ) | ||||
|
Cash flows from investing activities
|
||||||||
|
Proceeds from sale of interest in Gambitious
|
$ | 20,309 | $ | - | ||||
|
Net cash provided by investing activities
|
20,309 | - | ||||||
|
Cash flows from financing activities
|
||||||||
|
Proceeds from the issuance of common stock, net of issuance costs
|
$ | 624,116 | $ | 179,242 | ||||
|
Net cash provided by financing activities
|
624,116 | 179,242 | ||||||
|
Effect of exchange rate changes on cash
|
(35,200 | ) | (1,017 | ) | ||||
|
Net (decrease) / increase in cash
|
180,539 | (351,796 | ) | |||||
|
Cash and cash equivalents, beginning of year
|
233,068 | 891,592 | ||||||
|
Cash and cash equivalents, end of year
|
$ | 413,607 | $ | 539,796 | ||||
|
Supplemental cash flow disclosures
|
||||||||
|
Interest paid
|
$ | (5,982 | ) | $ | (3,807 | ) | ||
|
Non-cash investing and financing activities
|
||||||||
|
Change in accrued expenses related to non- employee share based payments
|
$ | 61,302 | $ | - | ||||
| Reallocation of noncontrolling interests | $ | 129,918 | $ | - | ||||
|
March 31,
2015
|
December 31,
2014
|
|||||||
|
Current assets
|
$
|
47,511
|
$
|
43,497
|
||||
|
Current liabilities
|
$
|
122,107
|
$
|
121,521
|
||||
|
March 31,
2015
|
December 31,
2014
|
|||||||
|
Advisory and professional costs
|
$ | 25,989 | $ | 44,591 | ||||
|
Travel and hotel costs
|
1,878 | 4,478 | ||||||
|
Development costs
|
2,113 | 14,174 | ||||||
|
Management fees
|
3,993 | 11,190 | ||||||
|
Interest
|
10,293 | 10,717 | ||||||
|
Wage tax return
|
18,806 | 17,992 | ||||||
|
Holiday pay allowance/Net salary
|
20,574 | 53,555 | ||||||
|
Penalty waiver
|
14,630 | 14,630 | ||||||
|
Marketing costs
|
- | 70,347 | ||||||
|
Accrued stock liability
|
28,911 | 21,841 | ||||||
|
VAT related to Symbid Coop.
|
- | 10,828 | ||||||
|
Other current liabilities
|
25,512 | 17,197 | ||||||
| $ | 152,699 | $ | 291,540 | |||||
|
March 31,
2015
|
December 31,
2014
|
|||||||
|
Working capital facility
|
$
|
114,869
|
$
|
128,685
|
||||
|
Subordinated loan – related party
|
72,641
|
81,378
|
||||||
|
Total notes payable
|
187,510
|
210,063
|
||||||
|
Less - Current Maturities
|
(105,464
|
)
|
(118,149
|
)
|
||||
|
Notes payable, less current maturities
|
$
|
82,046
|
$
|
91,914
|
||||
|
1.
|
Long term loan for approximately $197,000, bears interest of approximately 6.4% and is payable quarterly with principal. The loan decreases on a quarterly basis by approximately $ 9,000, starting on September 30, 2012. As of March 31, 2015 the loan balance was $ 114,869.
|
|
2.
|
A line of credit of approximately $ 66,000 with a floating interest rate of approximately 8.15% at March 31, 2015 and December 31, 2014. The balance on the credit facility at March 31, 2015 was $ 0.
|
|
1.
|
Assets of the Company including receivables and intellectual property developed by the Company.
|
|
2.
|
Guarantee by principal members of management up to approximately $ 60,000.
|
|
3.
|
Guarantee by the Netherlands government for the remaining balance in a hypothetical liquidation up to approximately $ 264,000.
|
|
As of
|
||||
|
March 31,
2015
|
||||
|
2015
|
$
|
105,464
|
||
|
2016
|
32,823
|
|||
|
2017
|
32,810
|
|||
|
2018
|
16,413
|
|||
|
$
|
187,510
|
|||
|
March 31,
2015
|
March 31,
2014
|
|||||||
|
Symbid Coop - 100%
|
$ | 5,146 | $ | 10,412 | ||||
|
Symbid Italia – 49.9%
|
7,702 | - | ||||||
|
Gambitious Coop
|
- | 606 | ||||||
|
Total net loss attributable to noncontrolling interests
|
$ | 12,848 | $ | 11,018 | ||||
|
March 31,
2015
|
December 31,
2014
|
|||||||
|
Symbid Coop - 100%
|
$ | (74,596 | ) | $ | (78,025 | ) | ||
|
Symbid Italia – 49.9%
|
133,362 | - | ||||||
|
Total equity (deficit) attributable to noncontrolling interests
|
$ | 58,766 | $ | (78,025 | ) | |||
|
|
March 31,
|
December 31,
|
||||||
|
|
2015
|
2014
|
||||||
|
Investor Warrants
|
||||||||
|
Implied starting stock price
|
$ | 0.42 | $ | 0.40 | ||||
|
Volatility
|
50 | % | 50 | % | ||||
|
Drift
|
0.46%-0.61 | % | 0.64%-0.84 | % | ||||
|
Exercise price
|
$ | 0.75 | $ | 0.75 | ||||
|
Minimum exercise price
|
$ | 0.01 | $ | 0.01 | ||||
|
Warrant shares
|
5,853,530 | 5,853,530 | ||||||
|
Event date
|
May 20, 2015
|
January 31, 2015
|
||||||
|
Maturity
|
December 5, 2016 – May 20, 2017
|
December 5, 2016 – May 20, 2017
|
||||||
|
Shares outstanding
|
34,698,982 | 33,182,100 | ||||||
|
|
March 31,
|
December 31,
|
||||||
|
|
2015
|
2014
|
||||||
|
Broker Warrants
|
||||||||
|
Implied starting stock price
|
$ | 0.42 | $ | 0.40 | ||||
|
Volatility
|
50 | % | 50 | % | ||||
|
Drift
|
0.46%- 0.52 | % | 0.64%-0.71 | % | ||||
|
Exercise price
|
$ | 0.50 | $ | 0.50 | ||||
|
Minimum exercise price
|
$ | 0.01 | $ | 0.01 | ||||
|
Warrant shares
|
93,000 | 93,000 | ||||||
|
Event date
|
May 20, 2015
|
January 31, 2015
|
||||||
|
Maturity
|
December 5, 2016 – February 5, 2017
|
December 5, 2016 – May 20, 2017
|
||||||
|
Shares outstanding
|
34,698,982 | 33,182,100 | ||||||
|
Three Months Ended March 31, 2015
|
||||||||||||||||||||
|
December 31, 2014 Fair Value of Warrant Liability
|
Fair Value of Warrants Issued
|
Change in Fair value of Warrant Liabilities
|
Reclassification
of Warrants
to Equity at
March,
31, 2015
|
March 31, 2015 Fair Value of Warrant Liability
|
||||||||||||||||
|
Investor Warrants
|
$ | 151,763 | $ | - | $ | 9,997 | $ | (18,097 | ) | $ | 143,663 | |||||||||
|
Broker Warrants
|
1,391 | - | - | (1,391 | ) | - | ||||||||||||||
|
Total
|
$ | 153,154 | $ | - | $ | 9,997 | $ | (19,488 | ) | $ | 143,663 | |||||||||
|
For the year ended
December 31,
|
Shares of Restricted Common Stock
|
|||
|
2015
|
250,000 | |||
|
2016
|
500,000 | |||
|
2017
|
250,000 | |||
| 1,000,000 | ||||
|
●
|
Limited or no structured distribution channels for SME finance other than banks, increasing the mismatch between entrepreneurs and financiers;
|
|
●
|
No centralized platform for (alternative) financiers, making it difficult and inefficient to find the right financier at the right time;
|
|
●
|
No standardized data protocols for SME data, leading to costly and time-intensive (offline) screening and monitoring;
|
|
●
|
Limited financial skills of entrepreneurs leading to unnecessary inefficiencies and obstacles within the financing process; and
|
|
●
|
Decline in bank financing due to new regulations and recent financial crises, leaving a vacuum in the life cycle of SME financing.
|
|
●
|
The Funding Network saw a funding volume of $40 million in its first month of operations;
|
|
●
|
The Funding Network added 1,750 new users to our community of now over 30,000 users;
|
|
●
|
We had a crowdfunding volume of EUR 1 million, resulting in a total crowdfunding volume since inception of EUR 7.5 million at end of period;
|
|
●
|
We recorded first revenues from paid registrations to The Funding Network.
|
|
Three months ended
|
||||||||
|
March 31,
|
||||||||
| 2015 | 2014 | |||||||
|
Revenues
|
||||||||
|
Crowdfunding
|
$ | 54,394 | 78,055 | |||||
|
Other
|
19,472 | 8,050 | ||||||
|
Total revenues
|
73,866 | 86,105 | ||||||
|
Operating expenses
|
||||||||
|
Selling, general and administrative
|
409,353 | 274,015 | ||||||
|
Professional fees
|
186,670 | 204,713 | ||||||
|
Research and development costs
|
22,242 | 45,975 | ||||||
|
Depreciation and amortization
|
36,938 | 334 | ||||||
|
Total operating expenses
|
655,203 | 525,037 | ||||||
|
Operating loss
|
(581,337 | ) | (438,932 | ) | ||||
|
Other income (expense)
|
||||||||
|
Fair value adjustment derivative liability - warrants
|
(7,274 | ) | 15,264 | |||||
|
Interest expense
|
(2,714 | ) | (5,810 | ) | ||||
|
Government subsidy
|
- | 8,221 | ||||||
|
Equity in losses of Gambitious B.V.
|
11,504 |
─
|
||||||
|
Other income and expense
|
- | (1,631 | ) | |||||
|
Total other income (expense)
|
1,516 | 16,044 | ||||||
|
Net loss
|
(579,821 | ) | (422,888 | ) | ||||
|
Net loss attributable to noncontrolling interests
|
(12,848 | ) | (11,018 | ) | ||||
|
Net loss attributable to Symbid Corp. stockholders
|
$ | (566,973 | ) | $ | (411,870 | ) | ||
|
Basic and diluted net loss per common share
|
$ | (0.02 | ) | $ | (0.02 | ) | ||
|
Weighted average number of shares outstanding
|
||||||||
|
Basic and diluted
|
34,079,498 | 26,498,864 | ||||||
|
Description
|
Amount in $
|
% of total
|
||||||
|
Working Capital
|
1,000,000
|
30
|
||||||
|
Expansion of Sales team
|
250,000
|
8
|
||||||
|
Additional Investments in Technology team
|
300,000
|
9
|
||||||
|
Investment in Big Data analyses
|
200,000
|
6
|
||||||
|
Implementation loan product offering
|
200,000
|
6
|
||||||
|
Expansion internal Finance function
|
100,000
|
3
|
||||||
|
Internationalization investments
|
200,000
|
6
|
||||||
|
Investor Relations budget
|
250,000
|
8
|
||||||
|
Marketing budget
|
400,000
|
12
|
||||||
|
Legal/compliance structure upgrade
|
150,000
|
5
|
||||||
|
OPTIONAL: acquisition of deal flow
|
250,000
|
8
|
||||||
|
Total
|
$
|
3,300,000
|
100
|
%
|
||||
|
●
|
should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;
|
|
●
|
have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;
|
|
●
|
may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and
|
|
●
|
were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.
|
|
Exhibit Number
|
Description of Exhibit
|
|
|
Certification of Principal Executive Officer and Pursuant to Rule 13a-14
|
||
|
Certification of Principal Financial Officer Pursuant to Rule 13a-14
|
||
|
32.1
*
|
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
|
|
|
32.2
*
|
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
|
|
|
101.INS
|
XBRL Instance Document
|
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
101.LAB
|
XBRL Taxonomy Extension Labels Linkbase Document
|
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
SYMBID CORP.
|
|||
|
May 15, 2015
|
By:
|
/s/ Korstiaan Zandvliet
|
|
|
Korstiaan Zandvliet, Chief Executive Officer
|
|||
|
SYMBID CORP.
|
|||
|
May 15, 2015
|
By:
|
/s/ Maarten van der Sanden
|
|
|
Maarten van der Sanden, Chief Financial Officer
|
|||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|